Altesa BioSciences, Inc.
🇺🇸United States
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Phase 2
Recruiting
- Conditions
- RhinovirusVirus Infection, RNAEnterovirus InfectionsRespiratory Tract DiseasesUpper Respiratory DiseaseUpper Respiratory DisorderInfections, RespiratoryCopdCOPD Exacerbation AcuteRhinovirus Infection
- Interventions
- Drug: PlaceboDrug: Vapendavir
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06149494
- Locations
- 🇬🇧
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU), London, United Kingdom
Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD
Phase 1
Completed
- Conditions
- Lower Respiratory DiseasePulmonary DiseaseHealthyRespiratory DiseaseCOPD
- Interventions
- Drug: Vapendavir
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05962645
- Locations
- 🇺🇸
Syneos Health Miami, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath